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Animal Heatstroke Models Execute the 
Empirical Triad Employed for the 
Diagnosis of Conventional 
Human Heatstroke
Heatstroke is a life-threatening disease defined as a
hyperpyrexia (> 40°C) and multiple organ (in particular,
the central nervous system [CNS]) dysfunction or fail-
ure. The CNS dysfunction includes delirium, convulsion,
or coma [1]. Neurologic injury has been ascribed to
metabolic disorders, edema of the brain, or cerebral
ischemia and damage [2,3]. Other organ dysfunctions
follow severe heatstroke, including hypotension, dis-
seminated intravascular coagulopathy (DIC), hepatic
failure, hyperventilation, pulmonary edema, renal fail-
ure, rhabdomyolysis, metabolic acidosis, and systemic
inflammation as shown in Table 1, [1,4–7]. DIC is
indicated by increased prothrombin time, activated par-
tial thromboplastin time, and D-dimer, and decreased
platelet count and protein C. Biochemical markers indi-
cate cellular ischemia and injury/dysfunction: plasma
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SUMMARY
This current review summarized animal models of heatstroke experimentation that promote our current knowledge
of therapeutic effects on cerebrovascular dysfunction, coagulopathy, and/or systemic inflammation with human
umbilical cord blood cells (HUCBCs) or estrogen in the setting of heatstroke. Accumulating evidences have
demonstrated that HUCBCs provide a promising new therapeutic method against neurodegenerative diseases,
such as stroke, traumatic brain injury, and spinal cord injury as well as blood disease. More recently, we have also
demonstrated that post- or pretreatment by HUCBCs may resuscitate heatstroke rats with by reducing circulatory
shock, and cerebral nitric oxide overload and ischemic injury. Moreover, CD34+ cells sorted from HUCBCs may
improve survival by attenuating inflammatory, coagulopathy, and multiorgan dysfunction during experimental
heatstroke. Many researchers indicated pro- (e.g. tumor necrosis factor-α [TNF-α]) and anti-inflammatory
(e.g. interleukin-10 [IL-10]) cytokines in the peripheral blood stream correlate with severity of circulatory shock,
cerebral ischemia and hypoxia, and neuronal damage occurring in heatstroke. It has been shown that intravenous
administration of CD34+ cells can secrete therapeutic molecules, such as neurotrophic factors, and attenuate
systemic inflammatory reactions by decreasing serum TNF-α but increasing IL-10 during heatstroke. Another
line of evidence has suggested that estrogen influences the severity of injury associated with cerebrovascular
shock. Recently, we also successfully demonstrated estrogen resuscitated heatstroke rats by ameliorating systemic
inflammation. Conclusively, HUCBCs or estrogen may be employed as a beneficial therapeutic strategy in preven-
tion and repair of cerebrovascular dysfunction, coagulopathy, and/or systemic inflammation during heatstroke.
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levels of blood urea nitrogen (BUN), creatinine, gluta-
mic oxaloacetic transaminase (SGOT), glutamic pyruvic
transaminase (SGPT), and alkaline phosphatase (Alp),
and cerebral levels of glycerol, glutamate, lactate/
pyruvate ratio, dihydroxy benzoic acid, lipid peroxidation,
oxidized-form glutathione, reduced-form glutathione,
dopamine, and serotonin are all raised during heat-
stroke. Intracranial pressure (ICP) is also elevated dur-
ing heatstroke. In contrast, the values of mean arterial
pressure (MAP), cerebral perfusion pressure (CPP =
MAP−ICP), and cerebral levels of local cerebral catalase,
glutathione peroxidase, and glutathione reductase activ-
ities are all significantly decreased during heatstroke.
In addition, it is well known that the lactate/pyruvate
ratio is a marker of cell ischemia, whereas glycerol is 
a marker of how severely cells are affected by ongoing
pathology [8–10]. Excessive accumulation of gluta-
mate has been shown in ischemic brain tissue [11–13].
Indeed, when the animals are exposed to hot environ-
ment, cerebral ischemia and hypoxia, which occurred
during heatstroke, were associated with an increased
production of glycerol, lactate/pyruvate ratio, glutamate,
and inducible nitric oxide synthase (iNOS)-dependent
NO in the brain [14–16]. In addition, PO2 in rat brain
was decreased after the onset of heatstroke. Thus, it
appears that excessive accumulation of glycerol, gluta-
mate, lactate/pyruvate ratio, and iNOS-dependent NO
in the brain may be secondary to cerebral ischemia,
hypoxia, and/or injury in the rat.
The empirical triad used for the diagnosis of classic
human heatstroke includes hyperpyrexia, CNS disor-
ders, and a history of heat stress [1]. Basing on this
triad, the anesthetized rat [4,17,18], the unanesthetized
rat [19–21], the unanesthetized rabbit [2], the unanes-
thetized mouse [22–24], the anesthetized mouse [25],
and the anesthetized baboon [26] all displayed a uni-
form response and reacted similarly to humans with
heatstroke. Table 1 summarizes signs and symptoms of
heatstroke in both humans and rats. It can be derived
from the table that the anesthetized rat model can
nearly resemble the full spectrum of signs and symptoms
occurring during heatstroke in humans. For this reason,
cerebrovascular dysfunction is an attractive target for
therapy in heatstroke.
Resuscitation from Experimental
Heatstroke by Transplantation of Human
Umbilical Cord Blood Cells
Neural transplantation has been used to study and
promote the regenerative potential of the brain after
an ischemic insult. Fetal neural stem cells can atten-
uate experimental brain injury and improve outcome
in stroke victims [27,28]. However, transplantation of
embryonic grafts is plagued with logistical and ethical
considerations. Thus, it is reasonable to seek alterna-
tive sources or an equivalent of stem cells. Stem cells
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Table 1. Symptoms and signs during heatstroke in both humans and rats
Symptoms and signs Humans* Rats†
1. Hyperpyrexia (↑core temperature) + +
2. Multiple organ dysfunction and failure: + +
Hypotension (↓mean arterial pressure) + +
ECG alterations + +
Hyperventilation (↓blood PCO2) + +
Pulmonary edema + +
Hepatic failure (↑glutamic oxaloacetic transaminase, + +
↑glutamic pyruvic transaminase, ↑alkaline phosphatase)
Renal failure (↑blood urea nitrogen, ↑creatinine) + +
Rhabdomyolysis (↑blood K+) + +
Disseminated intravascular coagulopathy (DIC: + +
↑prothrombin time, ↑activated partial thromboplastin time, 
↑D-dimer, ↓platelet count, ↓protein C)
Metabolic acidosis (↑blood lactate, ↓blood pH) + +
Systemic inflammation (↑pro-inflammatory cytokines) + +
Cerebral ischemia, injury, and dysfunction (ischemia: + +
↑glutamate, ↑intracranial pressure, ↓cerebral perfusion pressure,
↑lactate/pyruvate; damage: ↑glycerol; dysfunction: 
delirium, convulsion, or coma)
*Information from [1,5–7]; †information from [2,4,8–14]. DIC = disseminated intravascular coagulopathy; + = presence; ↑ = increased; ↓ = decreased.
have been isolated from various tissues in animals and
humans, including adult bone marrow, cord blood, and
even adult brain [29–35].
HUCBCs are rich in hematopoietic stem cells (CD34+
cells) [36]. Two percent of the HUCBCs are stem cells
capable of reconstituting blood lineages. These HUCBCs
have been used to reconstitute bone marrow and blood
cell lineages in children with malignant and nonmalig-
nant diseases [37]. HUCBCs is assumed to exhibit a
neuroprotective effect on the ischemic brain by multi-
potent stem cells derived from the nervous system with
the capacity to regenerate and give rise to cells belonging
to all three cell lineages in the nervous system: neurons,
oligodendrocytes, and astrocytes [46]. These cells could
be induced to express neural proteins [38–40]. When
the HUCBCs were administered via the tail vein, surviv-
ing HUCBCs were identified in the cortex and striatum
of the injured hemisphere [41–43]. The behavioral
dysfunctions produced by stroke [42–44], traumatic
brain injury [45], and spinal cord injury [46] were sig-
nificantly improved by intravenous delivery of HUCBCs.
Among these cells, only 2% expressed neuronal markers,
and 6% expressed glial fibrillary acidic protein. These
results indicated that there is a signal that can attract
the HUCBCs toward the site of ischemia and damage
and stimulate development of neural markers. However,
it is not known whether administration of HUCBCs
attenuates circulatory shock and cerebral ischemia
during heatstroke.
More recently, we have also demonstrated that
HUCBCs therapy may resuscitate rats with heatstroke
by reducing circulatory shock, and cerebral nitric oxide
overload and ischemic injury; central delivery of HUCBCs
seems superior to systemic delivery of HUCBCs in resus-
citating rats with heatstroke [15]. Our results, in part,
are consistent with previous findings concerning the effi-
cacy of transplanting HUCBCs as a treatment for con-
ventional stroke. It has been shown that intravenous
delivery of either whole bone marrow or umbilical cord
blood [42,45,47] can produce behavioral recovery.
Furthermore, previous results have revealed that
microvascular disturbances, including cerebral ischemia,
breakdown of the blood–brain barrier permeability, and
formation of cerebral vasogenic edema, occur during
heatstroke in rodents [2,48]. Therefore, the current
results indicated that after the onset of heatstroke, dis-
ruption of the blood–brain barrier may facilitate selective
entry of HUCBCs into the ischemic sites within the
brain [15]. Apparently, intracerebral administration had
some advantages in reaching the target sites in the brain
more easily than with the intravenous route of injection.
This can explain why intracerebroventricular delivery is
superior to intravenous delivery in resuscitation from
heatstroke. As demonstrated in our study, the prolon-
gation of survival among rats with HUCBCs transplants
was found to be related to maintenance of appropri-
ate levels of both MAP and CPP, as well as reduction in
both intracranial hypertension and cerebral neuronal
damage exhibited during the onset of heatstroke. The
maintenance of cerebral blood flow and PO2 in ani-
mals treated with HUCBCs might be brought about by
higher CPP resulting from lower ICP (due to reduction
in cerebral edema and cerebrovascular congestion) and
higher MAP during the development of heatstroke, as
demonstrated by our previous results [15].
Our previous results showed that the heatstroke-
induced arterial hypotension, cerebral ischemia, and
inducible nitric oxidase overexpression and NO over-
production in rat brain can be suppressed by pretreat-
ment with aminoguanide (an inducible nitric oxidase
inhibitor) [14]. In the following study, we also demon-
strated that HUCBCs transplantation attenuated arte-
rial hypotension, cerebral ischemia, and NO production
in rat brain during heatstroke. These findings together
suggest that HUCBCs transplantation may maintain
appropriate levels of systemic and cerebral circulation
during heatstroke by reducing cytokines production as
well as inhibiting inducible nitric oxidase-dependent NO
production in the brain.
It has been shown that HUCBCs could be induced to
express neural proteins [38], class III β-tubulin, glial fib-
rillary acidic protein, Galc (a marker of oligodendrocytes)
[39,40], and neurofilament microtubule-associated
protein 2 [49]. When these cells were transplanted into
the neonatal subventricular zone, some of them differ-
entiated into neuronal and glial phenotypes within the
neurogenic region [50]. In addition, there was an in-
crease in glial-derived neurotrophic factor levels fol-
lowing HUCBCs transplantation after stroke [51]. It is
likely that HUCBCs, rather than adult peripheral blood
mononucleocytes (PBMCs), may release any mediators
(i.e. cytokines, NO, and endothelial or other neurotro-
phic factors), reduce hypotension, decrease intracranial
hypertension, and confer neuronal protection during
heatstroke.
Owing to their greater availability, feeble immuno-
genicity, and lower risk of mediating viral transmission,
HUCBCs have come out as an alternative to bone mar-
row [52]. Moreover, HUCBCs can mediate therapeutic
effects in several animal models of neurologic diseases,
including stroke [42,43,45,46]. Our studies involving
rats indicate that HUCBCs could potentially be an ex-
cellent source of cells for the treatment of heatstroke,
because they are widely available and have been used
clinically. However, additional studies in experimental
models are needed.
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Infusion of HUCBCs Protect Against
Cerebral Ischemia and Damage 
During Heatstroke in the Rat
Intravenously delivered HUCBCs found in the brain 
4 weeks after middle cerebral artery occlusion in the rat
were excessively localized to the ischemic hemispheres
[44]. As above-mentioned, intravenously delivered
HUCBCs had been shown to improve both morpho-
logic and functional recovery of heat-stroked rats [15].
However, to our knowledge, there is no evidence about
the preventive effects of HUCBCs administered before
the initiation of cerebral ischemia and injury. To extend
these findings, we examined both the morphologic and
functional alterations in the presence of HUCBCs or
PBMCs 24 hours before initiation of heatstroke. Here,
we successfully demonstrated that HUCBCs pretreat-
ment could be a good choice for preventing heatstroke
occurrence.
As compared with those of vehicle-pretreated or
PBMC-pretreated heatstroke rats, the values for both the
latency (interval between initiation of heatstress and
onset of heatstroke) and survival time (interval of onset
of heatstroke to death) were significantly greater in those
of HUCBC-pretreated heatstroke rats (79–81 minutes for
latency and 118–138 minutes for survival time). Further-
more, we also demonstrated 12 minutes after the termi-
nation of heat exposure in the PBMC-treated group, all
the MAP, CBF, brain PO2, and heart rate values were
significantly lower than those of the normothermic
controls (p < 0.05). On the other hand, the values 
of Tbr (brain temperature), Tco (colonic temperature),
and levels of glutamate, glycerol, lactate/pyruvate ratio,
and NO in the extracellular fluids of the striatum in the
PBMC-treated group were significantly higher 12 min-
utes after the termination of 68 minutes heat exposure
than in those of the normothermic controls. Heatstroke-
induced arterial hypotension, cerebral ischemia and
hypoxia, and increased levels of glutamate, glycerol,
lactate/pyruvate ratio, and NO in the extracellular 
levels of striatum were significantly attenuated by pre-
treatment with HUCBCs 24 hours before the initiation
of heat exposure.
In our previous results, we also illustrated after the
onset of heatstroke, animals pretreated with PBMCs dis-
played higher values of striatal neuronal damage score
and iNOS immunoreactivity compared with those of
normothermic controls. In addition, histopathologic
verification revealed that heatstroke caused cell body
shrinkage, pyknosis of the nucleus, loss of Nissl sub-
stance, disappearance of the nucleolus, and overexpres-
sion of iNOS (inducible NO synthetase) in the striatum
of the PBMC-pretreated rats. However, with the HUCBCs
pretreatment neuroprotection was ensured. And deliv-
ered HUCBCs were localized to brain as determined by
immunohistochemistry and polymerase chain reaction
during heatstroke.
Pretreatment [53] or post-treatment [15] with
HUCBCs significantly attenuates the arterial hypoten-
sion, cerebral ischemia and hypoxia, and increased lev-
els of ischemia and damage markers in the brain during
heatstroke. These findings demonstrate that HUCBCs
are effective for prevention and repair of circulatory
shock and ischemic damage in the brain during heat-
stroke by reducing iNOS-dependent NO formation in the
brain. However, treatment with PBMC fails to produce
any significant protection. We attribute the discrepancy
between PBMCs and HUCBCs treatments to the lack of
pleuropotential of PBMCs. The results we obtained have
further shown that HUCBCs have an ability to prevent
circulatory shock and brain ischemic damage during the
heatstroke and, moreover, HUCBCs administered right
after the onset of heatstroke is still effective for improving
circulatory shock and ischemic damage in the brain.
Intravenously delivered HUCBCs found in the brain
after the onset of heatstroke were localized to the ische-
mic hemisphere. Moreover, immunofluorescent localiza-
tion of the HUCBCs by human nuclei detection suggested
that their numbers were large and widely distributed
to different brain structures. The intravenously injected
HUCBCs may be following homing signals that attract
them to the injured site [42,54], in particular the hyper-
thermic brain. In addition, intravenous administration
of HUCBCs can secrete therapeutic molecules, such as
neurotrophic factors, which when exogenously adminis-
tered by themselves are neuroprotective in stroke models;
the surviving cells, when administered intravenously, were
identified in the injured hemisphere [55,56]. In our previ-
ous results, the HUCBCs grafts probably promote neuro-
protection against heatstroke-induced neuronal damage
via the inhibition of iNOS/NO based on the decrease
of those concentration and N-methyl-D-aspartate in
brain [53,57]. Indeed, the notion that stem cells exert
an inherent neuroprotective effect was introduced by
Ourednik et al [58] and Teng et al [59] and has gained
great traction. Moreover, HUCBCs pretreatment can
maintain an appropriate level of MAP during heat-
stroke by reducing overproduction of cytokines as well
as depression of baroreceptor sensitivity. From these
results, the possible involvement of neurotrophic factors
secreted by HUCBCs cannot be completely eliminated.
Although the surviving HUCBCs were identified in dif-
ferent brain structures after the onset of heatstroke,
the CNS availability of grafted cells is not a prerequisite
for acute neuroprotection provided that therapeutic
molecules secreted by these cells could cross the
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blood–brain barrier [55]. In addition, there may be
some beneficial ingredients in the HUCBCs preparation,
but it remains to be determined whether this must be
delivered with intact cells [60].
Finally, it should be accentuated that it is still some-
what difficult to conceive whether a cellular pretreat-
ment therapy would have practical application except
the most extreme and risky circumstances. Clinical 
application for this indication may be considered until
mechanisms and parameters for beneficial outcomes
are better defined.
CD34+ Cells may Improve Survival During
Experimental Heatstroke by Ameliorating
Inflammatory, Coagulatory, and
Multiorgan Dysfunction
The above-mentioned issues demonstrated that HUCBCs
are effective for prevention and repair of cerebrovas-
cular dysfunction during heatstroke. However, the role
of CD34+ cells contained within HUCBCs in protecting
against heatstroke-induced multiorgan dysfunction and
failure should be explored.
In fact, after the onset of heatstroke, ischemic injury
is noted to occur in different brain structures, including
striatum, hypothalamus, cortex, and thalamus [61,62].
In our previous study, the striatum is chosen as a rep-
resentative region for the measurement of blood flow,
PO2, cellular ischemia and injury markers, and neuronal
damage scores. In our following study, the isolation of
CD34+ hematopoietic progenitor cells is performed by
positive selection of CD34+ expressing cells. Mononuclear
cells from human umbilical cord blood are obtained by
density gradient centrifugation over Ficoll Pague [63].
With the CD34+ Progenitor Cells Isolation Kit, hemato-
poietic progenitor cells, present at a frequency of about
2% in cord blood, can be rapidly and efficiently enriched
to a purity of about 98%. Intravenously delivered CD34+
progenitor cells found in the brain after the onset of
heatstroke were localized to all ischemic structures inclu-
ding cortex, hypothalamus, hippocampus, striatum,
cerebellum, and brain stem [61,62]. Immunofluorescent
localization of the CD34+ cells by human nuclei detec-
tion indicated that their numbers were large and widely
distributed to all the brain structures studied also. The
intravenously administered CD34+ cells may be following
homing signals that attract them to the ischemic or dam-
aged structures [42,54,64], in particular the hyperther-
mic brain, which had similar results with the pretreated
HUCBCs study.
In addition, our unpublished data successfully dem-
onstrated that resuscitation with intravenous doses of
CD34+, but not CD34− cells, immediately at the onset
of heatstroke significantly and dose-dependently im-
prove survival during heatstroke. As mentioned before,
cerebrovascular dysfunction, hypercoagulable state (or
DIC), and systemic inflammation may contribute to the
multiple organ dysfunction and death. Intravenously
delivered CD34+ cells significantly attenuated all the
heatstroke-induced reactions during heatstroke, when
administered immediately at the onset of heatstroke.
In fact, it has been demonstrated that systemic admin-
istration of human cord blood-derived CD34+ cells to
immunocompromised mice subjected to stroke 48 hours
earlier induces neovascularization in the ischemic zone
and provides a favorable environment for neuronal re-
generation [65]. However, our results provided the first
evidence that the tissue ischemia and injury that occurred
during heatstroke can be repaired immediately by sys-
temic administration of CD34+ cells in the rat.
It has been shown that heatstroke causes overpro-
duction of TNF-α and IL-1 in both the CNS and the
peripheral blood stream; this is associated with arterial
hypotension, cerebral ischemia and neuronal damage,
and high mortality rate [66–68]. Activated inflammation
has also been shown to be related to the severity of
acute heart failure [69], septic shock [70], and circula-
tory shock [67]. The administration of an IL-1 receptor
antagonist or glucocorticoids immediately after the start
of heatstroke is able to attenuate circulatory shock and
cerebral ischemia and injury and to improve survival
during heatstroke. Our unpublished results further dem-
onstrated that treatment with CD34+ cells causes atten-
uation of arterial hypotension, intracranial hypertension,
and cerebral ischemia and damage during heatstroke
by reducing overproduction of TNF-α in the serum. On
the other hand, our findings further demonstrated that,
after the onset of heatstroke in rats, treatment with
CD34+ cells causes a significant increase in the serum
level of IL-10 accompanied by a reduction of the above-
mentioned heatstroke reactions. It is believed that IL-10
has important anti-inflammatory and immunosuppres-
sive properties through attenuation of TNF-α and other
proinflammatory cytokines [71]. Putting these obser-
vations together, it seems that CD34+ cells therapy may
ameliorate arterial hypotension and cerebral ischemia
and damage by increasing IL-10 but suppressing TNF-α
production. It is generally believed that both anti- and
pro-inflammatory reactions are normal components
of the same immune response, which correlatively battle
infection while preventing immune pathology [72].
In the meanwhile, our accumulated evidences showed
that CD34+ cells therapy may have attenuated the
heatstroke-induced cerebral ischemia and injury by
reducing iNOS-dependent NO and hydroxyl radical
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production in the CNS. Recent studies also indicated
that the expression of several neurotrophic factors (in-
cluding glial cell-derived neurotrophic factor [GDNF])
in the brain was influenced by ischemia [73–75]. A
more recent report further demonstrated that mes-
enchymal stem cells that produce neurotrophic factors
reduced ischemic damage in the rat middle cerebral
artery occlusion model [76]. Similarly, our unpublished
results showed that CD34+ cells inducing endogenous
GDNF expression attenuated cerebral ischemia and
injury in the rat heatstroke model. Further studies are
required to verify whether the cerebral ischemia and
injury during heatstroke can be suppressed by exoge-
nous administration of GDNF.
In conclusion, from the above-unpublished data,
we successfully demonstrated that CD34+ cells sorted
from HUCBCs cause attenuation of cerebrovascular
dysfunction, hypercoagulable state, and activated inflam-
mation during experimental heatstroke.
Resuscitation from Experimental
Heatstroke by Estrogen Therapy
In the past, a large number of studies demonstrated
that estradiol influences cognition, the incidence and
progression of Alzheimer’s disease, and the severity of
injury associated with cerebrovascular stroke [77–79].
These researchers indicated that estrogen replacement
therapy lowers the risk or the severity of neurodegener-
ative decline associated with cerebrovascular stroke.
Since estradiol influences numerous aspects of CNS
function, understanding the cellular and molecular
mechanisms that underlie possible protective actions
is essential in preventing the deleterious consequences
of a prolonged hypoestrogenic state and improving the
women’s health. Animal models have been advanced
to examine estrogen’s ability to protect against brain
injury. Designs have been developed to mimic cerebral
ischemia that occurs with stroke by blocking of one 
or more cerebral arteries to produce a reproducible
infarct in the brain. These experimental manipulations
supply forceful proof that estradiol is a neuroprotective
factor. Furthermore, estrogen replacement in ovariec-
tomized (OVX) adult female rats significantly restores
protection of the brain to a level similar to that observed
in intact animals [80–82]. An ovarian factor involved
in the protection was suggested by the finding that
ovariectomy eliminates the endogenous protective effect
observed in female rats following cerebral ischemia.
Additionally, serum estradiol levels have been shown
to correlate inversely with ischemic stroke damage in
female rats [83].
In addition, estrogen appears to display immuno-
protective effects on macrophage functions potentially
by downregulating anti-inflammatory cytokine release
[84]. Estrogen-induced changes in T cell cytokine pro-
duction have also been demonstrated in experimental
models of cell-mediated acute inflammatory disease,
such as stroke. Furthermore, estrogen treatment of
interferon-γ (IFN-γ) deficient mice resulted in a signi-
ficant reduction in disease severity. Estrogen-treated
mice had lower levels of cytokine and chemokine pro-
duction and had reduced levels of chemokine receptor-
positive cells in the CNS [85]. Although estrogen has
been shown to effect multiple cellular components of
the immune system in ways that are not at first glance
consistent, as in the case of Th1 and Th2 phenotype.
Descriptions for these differences may reside in the
diversions of the immune mechanisms involved in these
models. Additionally, through understanding how estro-
gen can produce various results in different systems,
one should consider the general biology of estrogens
and how it would be expected to interact with the
immune system. A fatal aspect of estrogen’s biology is
its ability to support cell proliferation and survival. In
correspondence with this biology, estrogens appear to
augment B cell survival and T cell proliferation, though
not in every system studied [86].
Kim et al indicated that estrogen may act to show
preference for T cells toward a Th2 phenotype. Support
for estrogen enhancement of Th2 responses, specifi-
cally, is provided by studies in experimental autoimmune
encephalomyelitis (EAE) models. The amelioration of
EAE by estrogen was strongly correlated with enhanced
in vitro IL-10 production by specific T cells [87]. IL-10 is
a pleiotropic cytokine with a broad spectrum of bio-
logic effects on lymphoid and myeloid cells. One of the
known functions of IL-10 is its ability to inhibit the
production of pro-inflammatory mediators, including
IFN-γ, TNF-α, IL-6, IL-1, granulocyte-macrophage colony
stimulating factor, and the generation of NO by
lipopolysaccharide-activated monocytes/macrophages.
Nevertheless, the molecular mechanisms underlying the
anti-inflammatory effects of these cytokines remain
unknown [88,89].
According to several studies and our previous results,
both morbidity and mortality occurred in heatstroke
may be related to endotoxemia and the release of IL-1
[90,91]. The cerebral ischemia associated with heat-
stroke can be attenuated by pretreatment of animals
with an IL-1 receptor antagonist; here, the heatstroke
rodents produced much more proinflammatory cyto-
kines such as IL-1, IL-6, TNF-α, and IFN-γ [61,91,92].
Indeed, we successfully demonstrated that estrogen
replacement may improve survival during heatstroke
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by ameliorating inflammatory responses and cardio-
vascular dysfunction [93]. In the study, we measured
the cardiovascular responses of normal adult male and
female rats with or without estrogen replacement dur-
ing heatstroke. In addition, we determined the effects
of estrogen replacement with premarin (United States
Pharmacopeia) 1 mg/kg intravenously [93], immediately
after the onset of heatstroke, on cardiovascular responses
in surgically or chemically (leuprolide 100 μg/kg/day
was administered subcutaneously beginning 4 weeks
before heat stress) [95] OVX rats on production of
TNF-α [96] and IL-10 [97]. Humans with exertional
heatstroke were found to have a high level of IL-10 in
the serum [98]. However, in the rats with nonexertional
heatstroke, the serum levels of IL-10 were undetectable
[98]. After the onset of heatstroke in rats, treatment
with premarin produces a significant increase in the
serum level of IL-10 accompanied by a reduction of
heatstroke reactions. This implies that premarin may
ameliorate cerebral ischemia and damage by increasing
IL-10 but decreasing TNF-α production.
As compared with the estrus female rats, the OVX
rats, the leuprolide treated rats, and male rats all had
lower levels of plasma estradiol and lower survival time
values during heatstroke [93]. However, after an intra-
venous dose of premarin, both the plasma estradiol and
survival time values were significantly increased. Com-
pared with the normothermic controls, the vehicle-
treated male and OVX rats all displayed higher levels 
of serum TNF-α, prothrombin time, activated partial
thromboplastin time, D-dimer, BUN, creatinine, SGOT,
SGPT, and Alp, as well as cerebral levels of glycerol,
glutamate, and lactate/pyruvate ratio, and decreased
platelet counts and protein C levels. These heatstroke-
related reactions could be suppressed by premarin
therapy. In particular, the serum levels of IL-10 in these
groups were significantly elevated by premarin during
heatstroke [93]. The heatstroke-induced hyperpyrexia,
arterial hypotension, intracranial hypertension, cere-
bral hypoperfusion, hypoxia, and ischemia, renal and
hepatic failure, hypercoagulable state, and systemic
inflammation were all significantly attenuated by pre-
marin therapy in OVX rats. Therefore, estrogen replace-
ment may improve survival during heatstroke by reducing
inflammatory responses, hypercoagulable state, and
cerebrovascular dysfunction.
These results are in part consistent with previous
investigations. For example, it has been shown that estro-
gen administration provides tissue protection from mid-
dle cerebral artery occlusion by increasing cerebral blood
flow [99]. The female proestrus rats have normalized
organ function at 24 hours after trauma-hemorrhage,
whereas male and female estrus (low serum estrogen
levels compared as female proestrus rats) animals have
shown a marked depression in cardiovascular function
[100]. The results indicate that the maintenance of
cardiac functions after severe blood loss is associated
with high levels of estradiol at the start of the experi-
ment. It has also been shown that estrogen produces a
significant increase in blood flow not only to reproduc-
tive tissues but also to skin, thyroid gland, pancreas,
spleen [101,102], coronary vasculature [94], and
brain [64].
Possible Mechanisms Put Forth by
HUCBCs or CD34+ Cells or 
Estrogen as a New Therapeutic 
Strategy in Heatstroke
The figure shows a scheme depicting events between the
exposure of rodents to a hot environment and death from
heatstroke, with known or proposed interrelationships
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Hot environment
↑RNS, ↑ROS
Tissue ischemia,
hypoxia
↑Tco, ↓Tbr
↓MAP ↑ICP
↓CPP
() ()
↓CBF, ↓cerebral PO2
Neuronal damage
Multiorgan failure
Heatstroke
Death
↑TNF-α
DIC
HUCBCs 
or CD34+ 
or estrogen
↑glutamate,
↑glycerol, ↑TNF-α
↑RNS, ↑ROS
Figure. Proposed scheme of the interacting sequence of
events occurring from the beginning of heat exposure to
heatstroke occurrence. Arrows indicate increased (↑) or
decreased (↓). Tco = core temperature; Tbr = brain temper-
ature; MAP = mean arterial pressure; ICP = intracranial pres-
sure; CPP = cerebral perfusion pressure; RNS = radical
nitrogen species; ROS = radical oxygen species; CBF = cere-
bral blood flow; TNF-α = tumor necrosis factor-α; DIC = dis-
seminated intravascular coagulopathy; (−) = reversal.
from the published and unpublished data. After the
onset of heatstroke, animals exhibit cutaneous vasodila-
tion, splanchnic vasoconstriction, hyperpyrexia, hypoten-
sion, and intracranial hypertension. In the CNS, cerebral
ischemia (caused by both hypotension and intracranial
hypertension) leads to neuronal damage due to both
the cessation of blood flow leading to oxygen and nutri-
ent deprivation and the initiation of a cascade as sec-
ondary mechanisms. This neurotoxic cascade involves
overloading of reactive oxygen and nitrogen species,
glutamate, dopamine, and serotonin, and cerebral
inflammation and activated coagulation. Similarly, in
the periphery, tissue ischemia in the splanchnic organs
(resulting from shifting blood to the skin) leads to
multiple organ failure and dysfunction due to both the
systemic inflammation and activated coagulation.
Therefore, measures, which are able to attenuate the
hypotension, hyperpyrexia, hypercoagulable state, sys-
temic inflammation, cerebral ischemia, and metabolic
acidosis, can be used to limit multiple organ dysfunction
or failure in heatstroke as shown in Table 2. For example,
heatstroke-induced hypotension, intracranial hyperten-
sion, cerebral hypoperfusion and hypoxia, hypercoagu-
lable state, systemic inflammation, and tissue ischemia
and injury in multiple organs can be improved by
HUCBCs or CD34+ cells. However, in the absence of
these agents, these heatstroke reactions can still be
improved by premarin adopted immediately after the
onset of heatstroke. Before initiation of heat stress, prior
manipulations with HUCBCs were also found to be able
to protect against heatstroke syndromes. In fact, treat-
ment combinations of CD34+ cells and estrogen seem
to have enhanced effects during heatstroke due to sim-
ilar therapeutic mechanisms over the systemic inflam-
matory reactions between these regimens (Chen and
colleagues, unpublished data).
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